214 related articles for article (PubMed ID: 38788009)
21. Taking advantage of neural development to treat glioblastoma.
Zhang Z; Lin CC
Eur J Neurosci; 2014 Sep; 40(6):2859-66. PubMed ID: 24964151
[TBL] [Abstract][Full Text] [Related]
22. Natural substances to potentiate canonical glioblastoma chemotherapy.
Arcella A; Sanchez M
J Chemother; 2021 Sep; 33(5):276-287. PubMed ID: 33468026
[TBL] [Abstract][Full Text] [Related]
23. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A
Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review.
Esemen Y; Awan M; Parwez R; Baig A; Rahman S; Masala I; Franchini S; Giakoumettis D
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269752
[TBL] [Abstract][Full Text] [Related]
25. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
26. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
27. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
Kim HJ; Kim DY
Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763
[TBL] [Abstract][Full Text] [Related]
28. Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives.
Shahcheraghi SH; Alimardani M; Lotfi M; Lotfi M; Uversky VN; Guetchueng ST; Palakurthi SS; Charbe NB; Hromić-Jahjefendić A; Aljabali AAA; Gadewar MM; Malik S; Goyal R; El-Tanani M; Mishra V; Mishra Y; Tambuwala MM
Pathol Res Pract; 2024 May; 257():155285. PubMed ID: 38653089
[TBL] [Abstract][Full Text] [Related]
29. Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.
Valdebenito S; D'Amico D; Eugenin E
Cancer Rep (Hoboken); 2019 Dec; 2(6):e1220. PubMed ID: 32729241
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms regulating glioma invasion.
Paw I; Carpenter RC; Watabe K; Debinski W; Lo HW
Cancer Lett; 2015 Jun; 362(1):1-7. PubMed ID: 25796440
[TBL] [Abstract][Full Text] [Related]
31. Glioblastoma multiforme: novel therapeutic targets.
Muir M; Gopakumar S; Traylor J; Lee S; Rao G
Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
[TBL] [Abstract][Full Text] [Related]
32. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
33. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
34. A novel treatment for glioblastoma: integrin inhibition.
Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
[TBL] [Abstract][Full Text] [Related]
35. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
36. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment.
Pinel S; Thomas N; Boura C; Barberi-Heyob M
Adv Drug Deliv Rev; 2019 Jan; 138():344-357. PubMed ID: 30414495
[TBL] [Abstract][Full Text] [Related]
37. Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.
Wu H; Liu J; Wang Z; Yuan W; Chen L
CNS Neurosci Ther; 2021 Oct; 27(10):1105-1117. PubMed ID: 34363319
[TBL] [Abstract][Full Text] [Related]
38. Emerging treatment strategies for glioblastoma multiforme.
Carlsson SK; Brothers SP; Wahlestedt C
EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma as a Novel Drug Repositioning Target: Updated State.
Hosseinalizadeh H; Ebrahimi A; Tavakoli A; Monavari SH
Anticancer Agents Med Chem; 2023; 23(11):1253-1264. PubMed ID: 36733195
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Jahan N; Lee JM; Shah K; Wakimoto H
Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
